Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to -$25.0 million.

  • Arrowhead Pharmaceuticals' Net Cash Flow rose 4867.22% to -$25.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $148.0 million, marking a year-over-year increase of 186230.8%. This contributed to the annual value of $124.3 million for FY2025, which is 110188.66% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Net Cash Flow of -$25.0 million as of Q4 2025, which was up 4867.22% from $96.8 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Net Cash Flow high stood at $232.5 million for Q1 2021, and its period low was -$141.5 million during Q3 2021.
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Net Cash Flow value was -$27.3 million (recorded in 2023), while the average stood at $2.9 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 243435.28% in 2021, then skyrocketed by 43571.43% in 2024.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Net Cash Flow stood at -$92.8 million in 2021, then skyrocketed by 201.68% to $94.4 million in 2022, then tumbled by 155.88% to -$52.7 million in 2023, then rose by 7.6% to -$48.7 million in 2024, then soared by 48.67% to -$25.0 million in 2025.
  • Its last three reported values are -$25.0 million in Q4 2025, $96.8 million for Q3 2025, and -$56.0 million during Q2 2025.